The DOI matches its Crossref record.
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
Open accessAbstract
Ecteinascidin 743 (ET-743), a highly promising marine-based antitumor agent presently in phase II clinical trials, has been shown to interfere with the binding of minor-groove-interacting transcription factors, particularly NF-Y, with their cognate promoter elements in vitro . We have shown that NF-Y is a central mediator of activation of transcription of the human P glycoprotein gene (MDR1) by a variety of inducers and that NF-Y functions by recruiting the histone acetyltransferase PCAF to the MDR1 promoter. In the present study, we tested whether ET-743 could block activation of the MDR1 promoter by agents that mediate their effect through the NF-Y/PCAF complex. We report that physiologically relevant concentrations of ET-743 abrogate transcriptional activation of both the endogenous MDR1 gene and MDR1 reporter constructs by the histone deacetylase inhibitors as well as by UV light, with minimal effect on constitutive MDR1 transcription. Notably, this inhibition does not alter the promoter-associated histone hyperacetylation induced by histone deacetylase inhibitors, suggesting an in vivo molecular target downstream of NF-Y/PCAF binding. ET-743 is therefore the prototype for a distinct class of transcription-targeted chemotherapeutic agents and may be an efficacious adjuvant to the treatment of multidrug-resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics
Scott, J. D., & Williams, R. M. (2002) · Chemical Reviews · doi:10.1021/cr010212u · Cited by 1,149
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Drugs from the seas - current status and microbiological implications
P., P., R., E., & R., E. (2002) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-002-1006-8 · Cited by 571
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
D'Incalci, M., & Galmarini, C. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0263 · Cited by 445
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390
DNA minor groove binders as potential antitumor and antimicrobial agents
Baraldi, P. G., Bovero, A., Fruttarolo, F., Preti, D., Tabrizi, M. A., Pavani, M. G., & Romagnoli, R. (2004) · Medicinal Research Reviews · doi:10.1002/med.20000 · Cited by 376
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S.-I., Popescu, N., et al. (2001) · Nature Medicine · doi:10.1038/91008 · Cited by 348
Garcia-Carbonero, R., Supko, J. G., Manola, J., Seiden, M. V., Harmon, D., Ryan, D. P., Quigley, M. T., Merriam, P., Canniff, J., Goss, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.098 · Cited by 294
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B
Cuevas, C., Pérez, M., Martín, M. J., Chicharro, J. L., Fernández-Rivas, C., Flores, M., Francesch, A., Gallego, P., Zarzuelo, M., de la Calle, F., et al. (2000) · Organic Letters · doi:10.1021/ol0062502 · Cited by 282
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., & D'Incalci, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00357-9 · Cited by 262
“Separate data by Minuzzo and colleagues [27] and Jin and associates [28] indicate the possibility that ET-743 aects the regulation of transcription by inhibiting the normal formation of complexes between the transcription factor nuclear factor y (NFY) and the CAAT box.”
MethodSelf-citationNF-Y and the transcriptional activation of CCAAT promoters
Dolfini, D., Gatta, R., & Mantovani, R. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.628970 · Cited by 260
Wu, C., Calcagno, A. M., & Ambudkar, S. V. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801020093 · Cited by 259
The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells
Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., & Arnold, J. C. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.033 · Cited by 157
Metadata
- Authors
- Jin, S., Gorfajn, B., Faircloth, G., & Scotto, K. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-06-06
- Volume
- 97
- Issue
- 12
- Pages
- 6775-6779
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2099134833
- Cited by
- 206
- References
- 0
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.